Q-omics provides the consensus-scored RBMX2P5 profile across patient tissues and cancer cell-line models. RBMX2P5 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RBMX2P5 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, RBMX2P5 RNA expression shows 6,281 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, THCA, and STAD as cancer lineages where RBMX2P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMX2P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMX2P5 survival associations across molecular data types. RBMX2P5 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMX2P5 RNA expression–survival associations across cancer types. High RBMX2P5 expression shows unfavorable associations in BRCA, THYM, SKCM, KIRC and ACC, but favorable associations in LUSC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .033). Together, the overview and detailed table identify BRCA as the clearest survival context for RBMX2P5 RNA expression.
This table summarizes RBMX2P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RBMX2P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMX2P5 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, LIHC, UCEC and PRAD. The THCA box plot shows higher RBMX2P5 RNA expression in normal versus tumor tissue (log2 FC = −0.050, t-test p = .029).
This table shows molecular features associated with RBMX2P5 in patient tissues and cancer cell lines. In patient samples, RBMX2P5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
